Shares of American pharmaceutical heavyweight Johnson & Johnson ($JNJ) started Monday trading on a dull note as the U.S.

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

Still given JNJ has most of the rights to market and sell icontrokinra, is there any pressing need to complete a full, ...

Johnson & Johnson (JNJ) shares have edged up roughly 0.4% since yesterday, continuing an upward stretch that has seen the ...

Johnson & Johnson (NYSE:JNJ – Get Free Report)’s stock price rose 1.2% during mid-day trading on Tuesday after Guggenheim upgraded the stock from a neutral rating to a buy rating. Guggenheim now has a ...

Johnson & Johnson (NYSE:JNJ – Free Report) had its target price lifted by Bank of America from $161.00 to $175.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price is back in rally mode. It is still early in the game, but the Q2 results ...

Protagonist Therapeutics eyes a Johnson & Johnson buyout interest, with blockbuster drug potential and high acquisition hopes ...